跳至主要内容
临床试验/JPRN-UMIN000043172
JPRN-UMIN000043172已完成未知

Research and development of a simple and non-invasive prosthesis fixation method using a magnetic attachment - Research and development of a simple and non-invasive prosthesis fixation method using a magnetic attachment

niversity of the Ryukyus0 个研究点目标入组 8 人开始时间: 2021年2月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
8

研究概览

简要总结

o adverse events were observed during the all-subject period. Patients with orbital defects had difficulty maintaining adhesion and could not complete the 6-month trial period. Patients with microtia completed the trial period, but it was still difficult to maintain adhesion, and the degree of satisfaction was low. Although there were individual differences in the degree of satisfaction among the areola and nipple patients, some patients had a high degree of satisfaction.

研究设计

研究类型
Interventional

入排标准

年龄范围
6years-old 至 90years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1)The person does not want to wear the prosthesis. (2)Judgment ability is immature or deteriorated, and there is a risk of accidental ingestion. (3)There is a wound on the part where the prosthesis will be attached. (4)Skin diseases with a high risk of dermatitis (pemphigus, congenital epidermolysis bullosa, etc.).

研究者

发起方
niversity of the Ryukyus

相似试验

尚未招募
不适用
A study to measure pressure changes in eye while a person undergoes surgery for spine fracture lying on his back during surgery
CTRI/2019/01/017211Department of Anaesthesiology
进行中(未招募)
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EGFR-Amplified Newly diagnosed glioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-003171-64-DEAbbVie Deutschland GmbH & Co.KG90
进行中(未招募)
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)
EUCTR2017-003171-64-NLAbbVie Deutschland GmbH & Co.KG40
进行中(未招募)
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EGFR-Amplified Newly diagnosed glioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-003171-64-GBAbbVie Deutschland GmbH & Co.KG90
已完成
2 期
Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular HypertensionOpen-Angle GlaucomaOcular Hypertension
NCT04910100Betaliq, Inc.226